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Evidence that the inhibition of Na/K-ATPase activity by FK506
involves calcineurin. We reported that cyclosporin A (CsA) inhibits
Na'7K-ATPase activity in specific segments of the rat nephron. In this
study, we tested the hypothesis that cyclosporin A reduces NaVK-
ATPase activity through inhibition of calcineurin. In T cells, cyclosporin A
and FK506 bind to immunophilins and inhibit the phosphatase activity of
calcineurin; Rapamycin and SDZ 220-384 also bind to immunophilins but
do not change calcineurin activity. Na47K-ATPase activity was measured
in microdissected rat proximal tubule (S2 subsegment), medullary thick
ascending limb (mTAL), and cortical collecting duct (CCD). First we
found that two inhibitors of calcineurin, pentafluorophenol (PFP, 100 mM)
and peptide 412 (1 mM), significantly reduced Na/K-ATPase activity in
the CCD by 78% and 70%, respectively. In CCDs, FK506 inhibited
NaVK-ATPase activity by 61 to 85% at concentrations of 1.5 to 6 ng/ml,
but not at 0.5 ng/ml. FKSO6 (6 ng/ml) inhibited Na/K-ATPase activity in
rnTALs by 56% but did not inhibit it in S2s or glomeruli. In contrast,
Rapamycin (12.5 ng/ml) did not change Na/K-ATPase activity in CCD5
or mTALs, but at a concentration of 12.5 .rg/ml did block the inhibitory
effect of FK506 (6 ng/ml) in both segments. SDZ 220-384 (600 ng/ml) did
not change Na/K-ATPase activity in CCDs. Thus, in CCDs and mTAIs:
(1) FK506, like cyclosporin A, inhibits Na4iK-ATPase activity; (2) Rapa-
mycin and SDZ 220-384 do not inhibit Na/K-ATPase activity; and (3)
Rapamycin prevents FK506-induced inhibition of Na/K-ATPase activity.
These responses may be explained by a direct inhibition of calcineurin activity
yielding lower Na/K-ATPase activity in CCDs and mTAIs.
Cyclosporin A and FK506 are potent immunosuppressive drugs
which prolong renal allograft survival [1, 2] but also result in
clinically significant nephrotoxicity [3, 4] and hyperkalemia [5, 6].
We reported that cyclosporin A (CsA) causes a dose-dependent
inhibition of Na/K-ATPase activity in some but not all seg-
ments of the rat nephron [7]. The mechanism by which cyclospo-
nfl A specifically inhibits Nat/K-ATPase activity is unknown.
Despite structural differences, cyclosporin A and FK506 inhibit
interleukin-2 (IL-2) transcription in T lymphocytes through sim-
ilar signal transduction pathways [8, 9]. In these lymphocytes,
cyclosporin A and FK506 bind to different cytosolic receptors
(immunophilins) and form drug receptor complexes which inhibit
the phosphatase activity of calcineurin, a calcium-dependent,
calmodulin-stimulated protein phosphatase. Inhibition of cal-
cineurin activity decreases IL-2 transcription by blocking dephos-
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phorylation of the IL-2 specific nuclear promoter factors [10, 11]
(Fig. 1).
Rapamycin is a new immunosuppressive drug which is structur-
ally related to FK506 and binds to the same intracellular immu-
nophilin but does not inhibit calcineurin activity [12]. Preliminary
data indicate that rapamycin exerts considerably less nephrotox-
icity than cyclosporin A or FK506 [13]. SDZ 220-384 is a
semi-synthetic derivative of cyclosporin A which binds to cyclo-
philin but does not inhibit calcineurin (personal communication,
Dr. Römer, Sandoz Corp.).
In addition to decreasing IL-2 transcription, calcineurin might
regulate Na/K-ATPase activity through dephosphorylation of
its catalytic subunit. For example, Middleton et al showed that
protein kinase C (PKC) was capable of phosphorylating the a
subunit and inhibiting NaVK-transport activity in intact renal
cells [14]. Bertorello et al reported that phosphorylation of the
catalytic subunit of Na/K-ATPase by PKC inhibits the activity
of the enzyme [15, 16]. Subsequently, Aperia et al demonstrated
that stimulation of proximal tubular Na/K-ATPase by an a
adrenergic agonist could be reversed by preincubation with either
FK506 or a specific peptide inhibitor of calcineurin [17]. Thus, we
reasoned that if calcineurin regulates Na/K-ATPase activity via
dephosphorylation, then drugs which inhibit calcineurin could
decrease Nat'K-ATPase activity. First we examined the critical
question, can inhibition of calcineurin reduce Na/K-ATPase
activity in unstimulated, isolated, intact nephron segments. For
these experiments we used the specific inhibitors of calcineurin,
PFP [18] and peptide 412 [17]. Next, we examined the hypothesis
that cyclosporin A inhibits Na/K-ATPase activity through
inhibition of calcineurin by comparing how FK506, Rapamycin,
and SDZ 220-384 influence Na17K-ATPase activity in the rat
nephron. These drugs were chosen because of their differential
effects on calcineurin activity.
Methods
Tissue preparation
Pathogen-free male Sprague-Dawley rats (75 to 100 g) were
anesthetized with Nembutal (2 glkg body weight i.p., Abbott
Laboratories, Chicago, Illinois, USA). The left kidney was selec-
tively perfused with ice-cold dissection solution containing 1
mg/mI of collagenase (Type A, Boehringer Mannheim, Indianap-
olis, Indiana, USA) and albumin (BSA, bovine serum albumin,
Sigma Chemical Co., St. Louis, Missouri, USA) and cut into
cortical and outer medullary slices which were incubated at 37°C
in the collagenase solution as described previously [19]. The
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T cell receptor
composition of the dissection solution was in (mM): NaCI 137, KC1
5, MgSO 0.8, Na2HPO4 0,33, KH2PO4 0.44, MgCl 1, Tris-HCI
10, and CaCI2 0.25. The following segments were isolated: gb-
meruli, proximal tubules (S2 subsegment), medullary thick as-
cending limbs (mTALs), and cortical collecting ducts (CCDs).
Experimental protocol
Microdissected tubules from each rat were divided in four
groups of 5 to 10 mm each: groups 1 and 2 were used to measure
total and ouabain-insensitive ATPase activity, respectively, while
groups 3 and 4 were used to measure total and ouabain-insensitive
ATPase activity when different concentrations of drug (FK506,
Rapamycin, SDZ 220-384, PFP, and peptide 412) were added.
Nat/K-ATPase activity was calculated by subtracting ouabain-
insensitive ATPase activity from total ATPase activity [20]. Ten to
30 glomeruli were microdissected and Na/K-ATPase activity
was normalized per glomerulus. Preliminary experiments demon-
strated a linear relationship between the number of gbomeruli and
Na/KtATPase activity (r = 0.996, Fig. 2).
Measurement of ATPase activity
Na7K-ATPase activity was measured under Vm conditions
using the 32P method of Doucet, Katz and Morel [20], as
described previously [7]. To measure total ATPase activity, tu-
bules (groups 1 and 3) were incubated in a solution composed of
(in mM): NaC1 50, KC1 5, MgCI2 10, EUTA 1, Tris-HC1 100,
Na2ATP 10 (Grade II, Sigma). To measure ouabain-insensitive
ATPase activity (groups 2 and 4), the incubation solution was
identical to the above except NaCl and KC1 were replaced by
Tris-HC1 and 2 mM ouabain (Sigma) was added [201. Different
concentrations of FK506 (0.5 to 6 ng/ml), a gift from Fujisawa
Corp., Rapamycin (12.5 ng/ml or 12.5 rg/ml), a gift from Wyeth
Corp., SDZ 220-384 (600 nglml), a gift from Sandoz Corp., PFP
(100 mM) (Sigma), and peptide 412 (1 mM) [17] (synthesized by
the microchemical facilities at Emory University) was added to
groups 3 and 4.
Na
Na Fig. 1. A diagram of calcineunn binding toimmunosuppressant-immunophilin complexes in
T cell activation and regulation of Na IK-
ATPase. Binding of specific antigen to the T
cell receptor begins a cascade of events that
result in transcription of interleukin-2 (IL-2).
Calcineurin causes a dephosphorylation of the
nuclear factor of activated T cells (NF-AT) that
binds to the IL-2 promotor region in T
lymphocytes. When bound to their respective
binding proteins, cyclosporin A (CsA) and
FK506 complex with calcineurin and inhibit
dephosphoiylation of NF-AT.<K506 I
Calculations
The amount of spontaneously hydrolyzed ATP and the specific
radioactivity of 32P were measured as described previously [7].
Enzyme activity for Na/KtATPase is reported in pmol ATP
hydrolyzed per m tubule length (or per glomerulus) per minute
(pmol/mm/min or pmol/glom/min) and calculated from the fol-
lowing formula:
ATPase activity = MR
— B/SRAjtubule length or number of glomeruli/min
where MR is measured radioactivity, B is the rate of spontaneous
ATP hydrolysis, and SRA is specific radioactivity. Spontaneous
hydrolysis averaged 7 to 10% of measured radioactivity.
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Fig. 2. The relationship between number of glomeruli in an assay and
Na /K-ATPase activity. NaIK-ATPase activity increased linearly (r =
0.996) with number of glomeruli.
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Fig. 3. Calcineurin inhibitors and Na /K-A TPase activity in the CCD.
PFP (100 mM) and peptide 412(1 mM) decreased NaIK-ATPase activity
by 78% and 70%, respectively. Symbols are (U) Control; () drug.
Statistics
The results are presented as mean SE from paired experi-
ments. N indicates the number of rats studied. For comparisons
between two groups, statistical significance was calculated using a
Student's t-test with a value of P < 0.05 being significant. For
comparisons between 3 groups, a one-way analysis of variance
(ANOVA) was used, followed by a multiple comparisons pro-
tected t-test to determine which groups were significantly differ-
ent.
Western analysis of calcineurin B protein expression
Microdissected tubules were emulsified in 50 .d of "High Test"
buffer containing various proteinase inhibitors. The composition
of "High Test" buffer is as follows: 0.125 M Tris HCI, 20% glycerol
(by vol), 6% SDS (by wt), leupeptin (10 mg/mi), chymostatin
(5 mg/mi), aprotinin (10 mg/mi), benzamidine (50 mM), PMSF (10
mg/mi), pepstatin (10 mg/mi) and sodium trypsin inhibitor (5
mg/mi). Total protein was measured spectrophotometrically at
595 nm using a BCA protein assay kit (Pierce Immunotechnology,
Rockford Illinois, USA) and size separated by sodium dodecyl
sulfate (SDS)-polyacrylamide gel (15%) electrophoresis. Protein
from S2s and mTALs was added to each lane along with a positive
control from the rat brain. Following size separation, proteins
were transferred to 0.45 j.tm nitrocellulose membranes (Gibco
BRL) by electroblotting [21] and incubated for one hour with
blocking buffer (TFBS-NFM). The composition of TTBS-NFM is
as follows: Tn-buffered saline (TBS, 20 mrvi Tris HCI, 0.5 M NaCl,
pH 7.5); Tween-20 (0.5% vol/vol), and non-fat dried milk (0.5%
wt/vol) (Carnation Co., Los Angeles, California, USA). Excessive
blocking buffer was removed and blots washed for 15 minutes with
TBS for a minimum of two washes.
Blots were then probed with monoclonal antibodies directed
against calcineurin beta subunit (Upstate Biotechnology Incorpo-
rated, Lake Placid, New York, USA). These primary antibodies
were diluted 1:800 in 15 ml of TTBS-NFM and the nitrocellulose
blots were incubated for four hours. Blots were then washed three
times for 15 minutes in TBS and then incubated with 20 ml of goat
anti-rabbit IgG antibody labeled with peroxidase (dilution
1:10,000). Excess secondary antibody was removed by washing
with TBS and chemibioluminescence was performed according to
the manufacturer's protocol (ECL Western Blot kit, Amersham
International) [22]. Bands detected on autoradiography were
analyzed using laser densitometry [23].
Results
Effect of calcineurin inhibitors on Na /K-A TPase activity
To assess the role of calcineurin in regulating Na/K-ATPase
activity, two specific inhibitors of calcineurin, PFP [18J and
peptide 412 [17], were incubated with CCDs. PFP (100 mM)
significantly (P < 0.02; N = 6) reduced CCD Na17K-ATPase
activity by 78%. Peptide 412 (1 mM), a sequence that overlaps the
autoinhibitory domain of caicineurin [17], decreased Na/Kt
ATPase activity by 70% in the CCD (P < 0.02; N = 6; Fig. 3).
These results provide strong support for the hypothesis that
calcineurin is involved in the regulation of Na/K-ATPase even
when activity has not been stimulated.
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Fig. 4. Effect of FK506 (6 ng/ml) on Na/K-ATPase activity in various
nephron segments. FKSO6 significantly decreased Na/K-ATPase activity
in CCDs and mTALs. There was no effect on Na/K-ATPase activity in
either glomeruli or the S2 subsegment of the proximal tubule. Symbols
are: (U) control; () FK506 6 ng/ml.
FK506 and Na/KtATPase activity
FK506 (6 ng/ml) inhibited Na/K-ATPase activity in CCDs by
85% (P < 0.03) and mTALs by 56% (P < 0.04, Fig. 4). In contrast,
FK506 did not change Na/K-ATPase activity in glomeruli or
S2s (Fig. 4). Three additional concentrations of FK506 were
examined in CCDs: a therapeutic concentration (3 ng/ml); a low
therapeutic concentration (1.5 ng/mI); and a subtherapeutic con-
centration (0.5 ng/ml). FK506 reduced Na/KtATPase activity
by 76% at 1.5 ng/mi (P < 0.01) and higher concentrations did not
cause a further decrease (Fig. 5). However, FK506 did not
significantly affect NaJK-ATPase activity at 0.5 ng/mi (Fig. 5).
Rapamycin and FK506 on Nat'K-ATPase activity
In contrast to FK506, Rapamycin (12.5 ngfml) did not inhibit
Na/K-ATPase activity in either CCDs (Fig. 6) or mTALs (Fig,
7). FK506 and Rapamycin bind to the same immunophilin, FK
binding protein (FKBP), and high concentrations of Rapamycin
have been shown to displace FK506 from FKBP [24]. Therefore,
if FK506 inhibits Na/K-ATPase activity because it blocks
calcineurin, pharmacologic concentrations of Rapamycin (12.5
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Fig. 5. Dose-response of FK506 on Na/K-ATPase activiiy in CCDs.
FK506 inhibited Na/K-ATPase activity at concentrations of 1.5, 3, and
6 ng/ml. However, there was no significant effect on Na/K-ATPase
activity at 0.5 nglml. Symbols are: (U) control; (iJ) FK506. Note: the data
for 6 nglml is taken from Figure 4.
Fig. 7. Effect of FK5OO vs. Rapamycin on NaIK-ATPase activity in
mTALs. FK506 (6 nglml) decreased Na/K-ATPase activity, while
Rapamycin (12.5 ng/ml) had no effect. As in the CCD, Rapamycin (12.5
gIml) prevented FK506-induced inhibition of enzyme activity. Symbols
are (•) Control; (0) drug.
FK506 Rapamycin Rapamycin 12.5 pg/mI
6ng/mI 12.5 ng/ml FK5O66ng/ml
Fig. 6. Effect of Rapamycin vs. FK506 on NaiK-ATPase activity in
CCDs. In contrast to inhibition of Na'iK-ATPase activity by FK506 (6
ng/ml), Rapamycin (12.5 ng/ml) did not change Na/K-ATPase activity.
Rapamycin (12.5 ig/ml) prevented FK506-induced inhibition of Na/K-
ATPase activity. Symbols are: (•) control; (0) drug. Note: the data for
FK506 (6 ng/ml) are taken from Figure 4.
gIml) could prevent FKSO6-induced inhibition of NaIK-AT-
Pase activity by displacing FK506 from FKBP. When CCDs and
mTA.Ls were incubated with both FK506 (6 ng/ml) and Rapamy-
cm (12.5 Wml), the inhibitory influence of FK506 on Na7K-
ATPase activity was not observed (Figs. 6 and 7).
Effect of SDZ 220-384 on Na/K4-ATPase activity
SDZ 220-384 binds to cyclophilin, the same immunophilin
which binds to cyclosporin A, but has no effect on calcineurin
activity (personal communication, Dr. Romer, Sandoz Corp.).
SDZ 220-384 (600 ng/ml) did not change Na/K-ATPase in the
CCD (control: 10 2 pmol/mm/min; SDZ 220-384: 11 4
pmol/mm/min, N = 6).
Role of calcineurin in regulating Na *IK±A TPase activity
In T cells, cyclosporin A and FK506 bind to distinct intracellu-
lar proteins (immunophilins), cyclophilin and FKBP, respectively
[24]. In vitro, the drug-receptor complexes, cyclosporin A-cycto-
philin and FK506-FKBP, bind to and inhibit the activity of
calcineurin, a calcium- and calmodulin-dependent serine/threo-
nine phosphatase [11]. Studies in T lymphocytes show that these
drug-receptor complexes inhibit calcineurin activity at concentra-
tions which decrease IL-2 transcription [12]. In fact, the impor-
tance of inimunophilin binding to FK506-induced inhibition of
calcineurin was demonstrated by Fruman et at who noted that a
pharmacologic concentration of Rapamycin (1 .rm) reversed the
inhibition of IL-2 transcription by FK.506 [121. Presumably, this
was due to displacement of FK506 from FKBP [12]. Lane et al
showed that calcineurin's phosphatase activity in peripheral blood
mononuclear cells (PBM) was inhibited by 1 M FK506-FKBP or
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Calcineurin B protein ezpression in microdissected tubules
To evaluate potential mechanisms for the sensitivity differences
in nephron segments, we examined calcineurin 13 subunit protein
expression in S2s and mTALs. As shown in Figure 8, a 16 kDa
band corresponding to the known size of calcineurin B was
detected in the S2 subsegment and in the mTAL, Laser densitom-
etry of the Western blot shown in Figure 8 demonstrated a relative
band density of 2.37 and 1.93 in two samples of S2s with 40 g
total protein, and one of 1.32 in the mTAL at twice the amount of
S2 protein. Control rat brain (100 g) showed a relative density of
7.88,
Discussion
Our major findings are: (1) inhibition of calcineurin reduces
Na7K-ATPase activity even in the basal state; (2) FK506, a drug
which binds to FKBP and inhibits calcineurin in T cells [12],
inhibits Na/K-ATPase activity in the same nephron segments
as cyclosporin A [7]; (3) Rapamycin and SDZ 220-384, drugs
which bind to immunophilins but do not change calcineurin
activity, do not inhibit Na/K-ATPase activity; (4) the segment-
specific effects of FK506 may be linked to the differential expres-
sion of calcineurin protein in the nephron.
Calcineurin B expression
4
in rat nephron
4#c
'4
16 kDA
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cyclosporin A-cyclophilin, but not by either drug or immunophulin
separately. However, up to 10 M Rapamycin-FKBP did not
change PBM calcineurin activity. They proposed that cyclosporin
A and FK506-induced immunosuppression results from drug-
immunophilin complexes blocking the phosphatase activity of
calcineurin [25].
Others have demonstrated that phosphorylation of the Nat'
K -ATPase catalytic subunit decreases enzyme activity in vitro
[14—16]. Bertorello and Aperia noted that stimulation of protein
kinase C activity by phorbol ester or diaglycerol significantly
reduced Na/KtATPase activity in the rat proximal tubule [16].
In related studies, Aperia et al found that inhibition of calcineurin
phosphatase activity by FK506 reversed a adrenergic mediated
stimulation of proximal tubule Nat'K-ATPase [17]. They em-
phasized that changes in phosphatase activity can modify enzyme
activity. Our studies extend these results in the following way by
showing that the inhibitory influence of FK506 can be seen even
when Nat'K-ATPase activity is not stimulated at least in the
mTAL and CCD. Moreover, we found that FK506 does not affect
Na/K-ATPase in the S2 segment possibly because there is
increased expression of calcineurin. Thirdly, differences in the
influence of other drugs in this category indicate that simply
binding to immunophilins (that is, FKBP or cyclophilins) is
insufficient to inhibit Nat'K-ATPase.
Nephron segment-specific inhibition of Na t/KtA TPase
It is intriguing that both FK506 and cyclosporin A [7] cause
segment-specific inhibition of Nat'K-ATPase activity along the
Fig. 8. Ca!cineurin B protein expression in rat
nephron. A 16 kDa band, consistent with the
size of Calcineurin B, was detected in the S2
(40 g protein/lanes 3 and 4) from two
experiments compared to a less dense band in
the mTAL (80 g protein/lane 2). Rat brain
(100 j.tg protein/lane 1) was used as a positive
control.
rat nephron. Because tissues with increased expression of cal-
cineurin are less sensitive to FK506 [26, 27], we reasoned that
different segments of the rat nephron might express varying
amounts of calcineurin. To address this hypothesis, we performed
Western blot analysis using a monoclonal antibody to Calcineurin
13 in FK506-sensitive (mTAL) and FK506-insensitive (S2)
nephron segments. We found greater Calcineurin f3 expression in
the S2 than in the mTAL (Fig. 8). Preliminary data demonstrating
that calcineurin enzyme activity in S2s is 20-fold greater than in
mTALs or CCDs [28] is also consistent with the hypothesis that
sensitivity to cyclosporin A or FK506 may be related to the
amount of calcineurin present. A second possibility is that there is
differential expression of isoforms of calcineurin or immunophil-
ins in different nephron segments. For example, one isoform of
cyclophilin, cyclophilin C, appears to be absent from the liver and
T cells of mice but is particularly abundant in the kidney [29]. A
third possibility is that cyclosporin A and FK506 interact to a
lesser or greater extent with various isoforms of Nat'K-ATPase.
However, we and others find no difference in a or J3 isoform
subunit expression in microdissected CCDs, mTALs, and S2s
using RT-PCR and Western analysis [30, 31].
Possible relationship between nephrotoxicity, inhibition of Na /
K -A TPase activity, and immunosuppressive mechanisms
Initial clinical experience with FK506 suggested that it was less
nephrotoxic than cyclosporin A [32]. However, more recent
studies indicate equivalent degrees of nephrotoxicity between the
Brain mTAL
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two drugs [33, 34]. Our data indicate a greater degree of Na/
K-ATPase inhibition in the CCD (Fig. 4) which is consistent with
the 100-fold greater potency of FK506 to inhibit IL-2 transcription
in T cells [9]. Moreover, the present results, along with our earlier
study [7], raise the possibility that both the immunosuppressive
and nephrotoxic effects of cyclosporin A and FK506 result from
the same biochemical event, namely inhibition of caleineurin
activity.
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